Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Roche Primes New Push Via Cipla For Avastin, Actemra In India

Executive Summary

Yesteryear rivals Roche and Cipla have sewn up a partnership under which Cipla will market a second brand of the Swiss giant’s Avastin (bevacizumab) and the

You may also be interested in...



Roche Bolsters India Partnering With Cipla, Entero To Handle Nephrology

Roche is pressing ahead with partnering deals in India as part of efforts to expand access to certain key existing brands and signals intent to continue to explore more collaborations wherever it needs to “reach out to more patients urgently.”

India Coronavirus Actions: Stock Checks, Kaletra Gx Readiness And Bulk Drugs

A string of actions to ensure medicines security and prioritize bulk drug project clearances are underway in India as the country enters a critical phase in its efforts to contain coronavirus cases.

Roche India Head On Way Out

Roche's India head, Lara Bezerra, seen as unconventional in her overall strategic approach, is heading out of the company. Speculation is rife that questions around "business deliverables" may have contributed to the decision.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

SC100473

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel